| |
| PBC |Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis |
|
|
|
|
| |
Gastroenterol Hepatol. 2019 Sep;17(10):2076-2084.e2. doi: 10.1016/j.cgh.2018.12.028.Epub 2019 Jan 4.
Angela C Cheung 1, Willem J Lammers 2, Carla F Murillo Perez 3, Henk R van Buuren 2, Aliya Gulamhusein 3, Palak J Trivedi 4, Konstantinos N Lazaridis 1, Cyriel Y Ponsioen 5, Annarosa Floreani 6, Gideon M Hirschfield 3, Christophe Corpechot 7, Marlyn J Mayo 8, Pietro Invernizzi 9, Pier Maria Battezzati 10, Albert Parés 11, Frederik Nevens 12, Douglas Thorburn 13, Andrew L Mason 14, Marco Carbone 9, Kris V Kowdley 15, Tony Bruns 16, George N Dalekos 17, Nikolaos K Gatselis 17, Xavier Verhelst 18, Keith D Lindor 19, Ana Lleo 9, Raoul Poupon 7, Harry L A Janssen 3, Bettina E Hansen 20, Global PBC Study Group
|
| |
|
|
| |
Author information
Abstract
Background & aims: Primary biliary cholangitis (PBC) predominantly affects middle-aged women; there are few data on disease phenotypes and outcomes of PBC in men and younger patients. We investigated whether differences in sex and/or age at the start of ursodeoxycholic acid (UDCA) treatment are associated with response to therapy, based on biochemical markers, or differences in transplant-free survival.
Methods: We performed a longitudinal retrospective study of 4355 adults in the Global PBC Study cohort, collected from 17 centers across Europe and North America. Patients received a diagnosis of PBC from 1961 through 2014. We evaluated the effects of sex and age on response to UDCA treatment (based on GLOBE score) and transplant-free survival using logistic regression and Cox regression analyses, respectively.
Results: Male patients were older at the start of treatment (58.3±12.1 years vs 54.3±11.6 years for women; P<.0001) and had higher levels of bilirubin and lower circulating platelet counts (P<.0001). Younger patients (45 years or younger) had increased serum levels of transaminases than older patients (older than 45 years). Patients older than 45 years at time of treatment initiation had increased odds of a biochemical response to UDCA therapy, based on GLOBE score, compared to younger patients. The greatest odds of response to UDCA were observed in patients older than 65 years (odds ratio compared to younger patients 45 years or younger, 5.48; 95% CI, 3.92-7.67; P<.0001). Risk of liver transplant or death (compared to a general population matched for age, sex, and birth year) decreased significantly with advancing age: hazard ratio for patients 35 years or younger, 14.59 (95% CI, 9.66-22.02) vs hazard ratio for patients older than 65 years, 1.39 (95% CI, 1.23-1.57) (P<.0001). On multivariable analysis, sex was not independently associated with response or transplant-free survival.
Conclusion: In longitudinal analysis of 4355 adults in the Global PBC Study, we associated patient age, but not sex, with response to UDCA treatment and transplant-free survival. Younger age at time of treatment initiation is associated with increased risk of treatment failure, liver transplant, and death.
|
|
|
|
| |
| |
|
| |
|
|
|
|
|
